Cardiovascular Risks Not Increased With Denosumab

(MedPage Today) -- AUSTIN, Texas – Denosumab (Prolia, Xgeva) carried no increased risk of cardiovascular disease or stroke when compared with zoledronic acid (Reclast, Zometa) to combat osteoporosis, researchers found. Compared with zoledronic...
Source: MedPage Today Cardiovascular - Category: Cardiology Source Type: news